Oral delivery of PND-1186 FAK inhibitor decreases tumor growth and spontaneous breast to lung metastasis in pre-clinical models

Cancer Biology and Therapy

Volumn 9, Issue 10, 2010, Pages 778-790

  Walsh, Colin ^a   Tanjoni, Isabelle ^a   Uryu, Sean ^a   Tomar, Alok ^a   Nam, Ju Ock ^a   Luo, Hong ^b   Phillips, Angelica ^b   Patel, Neela ^b   Kwok, Cheni ^b   McMahon, Gerald ^b   Stupack, Dwayne G ^c   Schlaepfer, David D ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b Poniard Pharmaceuticals Inc   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Apoptosis; FAK; Inflammation; Tumor growth; Tumor metastasis

Indexed keywords

ANTINEOPLASTIC AGENT; FOCAL ADHESION KINASE; FOCAL ADHESION KINASE INHIBITOR; INTERLEUKIN 6; PND 1186; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; STAUROSPORINE; TYROSINE; AMINOPYRIDINE DERIVATIVE; CRK ASSOCIATED SUBSTRATE PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BREAST CARCINOMA; CANCER INHIBITION; CANCER MODEL; CELL ADHESION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG HALF LIFE; ENZYME PHOSPHORYLATION; EXPERIMENTAL NEOPLASM; FEMALE; INFLAMMATORY INFILTRATE; LUNG METASTASIS; MAXIMUM PLASMA CONCENTRATION; METASTASIS INHIBITION; MOUSE; NONHUMAN; ONCOGENE K RAS; PROTO ONCOGENE; SPLENOMEGALY; TIME TO MAXIMUM PLASMA CONCENTRATION; APOPTOSIS; CELL INFILTRATION; DISTRIBUTION VOLUME; DRUG CLEARANCE; ENZYME INHIBITION; LEUKOCYTE; ONCOGENE BRAF; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; STROMA CELL; TUMOR CELL; TUMOR GROWTH; TUMOR VOLUME; ANIMAL; BAGG ALBINO MOUSE; BREAST TUMOR; CELL PROLIFERATION; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; HUMAN; LUNG TUMOR; METABOLISM; METASTASIS; MOUSE MUTANT; NUDE MOUSE; ORAL DRUG ADMINISTRATION; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

ADMINISTRATION, ORAL; AMINOPYRIDINES; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CRK-ASSOCIATED SUBSTRATE PROTEIN; FEMALE; FOCAL ADHESION PROTEIN-TYROSINE KINASES; HUMANS; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; MICE, SCID; PHOSPHORYLATION; TYROSINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79960150764     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.9.10.11433     Document Type: Article

References (50)

1. Nicolini A, Giardino R, Carpi A, Ferrari P, Anselmi L, Colosimo S, et al. Metastatic breast cancer: an updating. Biomed Pharmacother 2006; 60:19-21.
2. Weigelt B, Peterse JL, van 't Veer LJ. Breast cancer metastasis: markers and models. Nat Rev Cancer 2005; 5:591-602.
3. White DE, Muller WJ. Multifaceted roles of integrins in breast cancer metastasis. J Mammary Gland Biol Neoplasia 2007; 12:135-42.
4. Schlaepfer DD, Hauck CR, Sieg DJ. Signaling through focal adhesion kinase. Prog Biophys Mol Biol 1999; 71:435-78.
5. Mitra SK, Hanson DA, Schlaepfer DD. Focal adhesion kinase: in command and control of cell motility. Nat Rev Mol Cell Biol 2005; 6:56-68.
6. Cance WG, Harris JE, Iacocca MV, Roche E, Yang X, Chang J, et al. Immunohistochemical analyses of focal adhesion kinase expression in benign and malignant human breast and colon tissues: correlation with preinvasive and invasive phenotypes. Clin Cancer Res 2000; 6:2417-23. (Pubitemid 30399210)
7. Owens LV, Xu LH, Craven RJ, Dent GA, Weiner TM, Kornberg L, et al. Overexpression of the focal adhesion kinase (p125FAK) in invasive human tumors. Cancer Res 1995; 55:2752-5.
8. Su GH, Song JJ, Repasky EA, Schutte M, Kern SE. Mutation rate of MAP2K4/MKK4 in breast carcinoma. Hum Mutat 2002; 19:81.
9. Watermann DO, Gabriel B, Jager M, Orlowska-Volk M, Hasenburg A, zur Hausen A, et al. Specific induction of pp125 focal adhesion kinase in human breast cancer. Br J Cancer 2005; 93:694-8.
10. Pylayeva Y, Gillen KM, Gerald W, Beggs HE, Reichardt LF, Giancotti FG. Ras- and PI3K-dependent breast tumorigenesis in mice and humans requires focal adhesion kinase signaling. J Clin Invest 2009; 119:252-66.
11. Agochiya M, Brunton VG, Owens DW, Parkinson EK, Paraskeva C, Keith WN, et al. Increased dosage and amplification of the focal adhesion kinase gene in human cancer cells. Oncogene 1999; 18:5646-53.
12. Lark AL, Livasy CA, Dressler L, Moore DT, Millikan RC, Geradts J, et al. High focal adhesion kinase expression in invasive breast carcinomas is associated with an aggressive phenotype. Mod Pathol 2005; 18:1289-94.
13. Lightfoot HM, Lark A, Livasy CA, Moore DT, Cowan D, Dressler L, et al. Upregulation of focal adhesion kinase (FAK) expression in ductal carcinoma in situ (DCIS) is an early event in breast tumorigenesis. Breast Cancer Res Treat 2004; 88:109-16.
14. Oktay MH, Oktay K, Hamele-Bena D, Buyuk A, Koss LG. Focal adhesion kinase as a marker of malignant phenotype in breast and cervical carcinomas. Hum Pathol 2003; 34:240-5.
15. Zouq NK, Keeble JA, Lindsay J, Valentijn AJ, Zhang L, Mills D, et al. FAK engages multiple pathways to maintain survival of fibroblasts and epithelia: differential roles for paxillin and p130Cas. J Cell Sci 2009; 122:357-67.
16. Mitra SK, Mikolon D, Molina JE, Hsia DA, Hanson DA, Chi A, et al. Intrinsic FAK activity and Y925 phosphorylation facilitate an angiogenic switch in tumors. Oncogene 2006; 25:5969-84.
17. Lahlou H, Sanguin-Gendreau V, Zuo D, Cardiff RD, McLean GW, Frame MC, et al. Mammary epithelial-specific disruption of the focal adhesion kinase blocks mammary tumor progression. Proc Natl Acad Sci USA 2007; 104:20302-7.
18. Luo M, Fan H, Nagy T, Wei H, Wang C, Liu S, et al. Mammary epithelial-specific ablation of the focal adhesion kinase suppresses mammary tumorigenesis by affecting mammary cancer stem/progenitor cells. Cancer Res 2009; 69:466-74.
19. Hsia DA, Mitra SK, Hauck CR, Streblow DN, Nelson JA, Ilic D, et al. Differential regulation of cell motility and invasion by FAK. J Cell Biol 2003; 160:753-67.
20. Benlimame N, He Q, Jie S, Xiao D, Xu YJ, Loignon M, et al. FAK signaling is critical for ErbB-2/ErbB-3 receptor cooperation for oncogenic transformation and invasion. J Cell Biol 2005; 171:505-16.
21. Behmoaram E, Bijian K, Jie S, Xu Y, Darnel A, Bismar TA, et al. Focal adhesion kinase-related prolinerich tyrosine kinase 2 and focal adhesion kinase are co-overexpressed in early-stage and invasive ErbB-2-positive breast cancer and cooperate for breast cancer cell tumorigenesis and invasiveness. Am J Pathol 2008; 173:1540-50.
22. Mitra SK, Lim ST, Chi A, Schlaepfer DD. Intrinsic focal adhesion kinase activity controls orthotopic breast carcinoma metastasis via the regulation of urokinase plasminogen activator expression in a syngeneic tumor model. Oncogene 2006; 25:4429-40.
23. van Nimwegen MJ, Verkoeijen S, van Buren L, Burg D, van de Water B. Requirement for focal adhesion kinase in the early phase of mammary adenocarcinoma lung metastasis formation. Cancer Res 2005; 65:4698-706.
24. Shibue T, Weinberg RA. Integrin beta1-focal adhesion kinase signaling directs the proliferation of metastatic cancer cells disseminated in the lungs. Proc Natl Acad Sci USA 2009; 106:10290-5.
25. Slack-Davis JK, Martin KH, Tilghman RW, Iwanicki M, Ung EJ, Autry C, et al. Cellular characterization of a novel focal adhesion kinase inhibitor. J Biol Chem 2007; 282:14845-52.
26. Roberts WG, Ung E, Whalen P, Cooper B, Hulford C, Autry C, et al. Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271. Cancer Res 2008; 68:1935-44.
27. Shi Q, Hjelmeland AB, Keir ST, Song L, Wickman S, Jackson D, et al. A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth. Mol Carcinog 2007; 46:488-96.
28. Liu TJ, LaFortune T, Honda T, Ohmori O, Hatakeyama S, Meyer T, et al. Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo. Mol Cancer Ther 2007; 6:1357-67.
29. Halder J, Lin YG, Merritt WM, Spannuth WA, Nick AM, Honda T, et al. Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma. Cancer Res 2007; 67:10976-83.
30. Slack-Davis JK, Hershey ED, Theodorescu D, Frierson HF, Parsons JT. Differential requirement for focal adhesion kinase signaling in cancer progression in the transgenic adenocarcinoma of mouse prostate model. Mol Cancer Ther 2009; 8:2470-7.
31. Parsons JT, Slack-Davis J, Tilghman R, Roberts WG. Focal adhesion kinase: targeting adhesion signaling pathways for therapeutic intervention. Clin Cancer Res 2008; 14:627-32.
32. Tanjoni I, Walsh C, Uryu S, Nam JO, Mielgo A, Tomar A, et al. PND-1186 FAK inhibitor selectively promotes tumor cell apoptosis in three-dimensional environments. Cancer Biology & Therapy 2010; 9.
33. Heppner GH, Miller FR, Shekhar PM. Nontransgenic models of breast cancer. Breast Cancer Res 2000; 2:331-4.
34. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420:860-7.
35. Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009; 30:1073-81.
36. DeNardo DG, Coussens LM. Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res 2007; 9:212.
37. Dupre SA, Hunter KW Jr. Murine mammary carcinoma 4T1 induces a leukemoid reaction with splenomegaly: Association with tumor-derived growth factors. Exp Mol Pathol 2006; 82:12-24.
38. Hodge DR, Hurt EM, Farrar WL. The role of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer 2005; 41:2502-12.
39. Aslakson CJ, Miller FR. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 1992; 52:1399-405.
40. Hollestelle A, Elstrodt F, Nagel JH, Kallemeijn WW, Schutte M. Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines. Mol Cancer Res 2007; 5:195-201.
41. Chiang AC, Massague J. Molecular basis of metastasis. N Engl J Med 2008; 359:2814-23.
42. Provenzano PP, Inman DR, Eliceiri KW, Beggs HE, Keely PJ. Mammary epithelial-specific disruption of focal adhesion kinase retards tumor formation and metastasis in a transgenic mouse model of human breast cancer. Am J Pathol 2008; 173:1551-65.
43. Mitra SK, Schlaepfer DD. Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr Opin Cell Biol 2006; 18:516-23.
44. Lim S-T, Mikolon D, Stupack DG, Schlaepfer DD. FERM control of FAK function: Implications for cancer therapy. Cell Cycle 2008; 7:2306-14.
45. Zheng Y, Xia Y, Hawke D, Halle M, Tremblay ML, Gao X, et al. FAK phosphorylation by ERK primes rasinduced tyrosine dephosphorylation of FAK mediated by PIN1 and PTP-PEST. Mol Cell 2009; 35:11-25.
46. Zhao J, Guan JL. Signal transduction by focal adhesion kinase in cancer. Cancer Metastasis Rev 2009; 28:35-49.
47. DeNardo DG, Johansson M, Coussens LM. Immune cells as mediators of solid tumor metastasis. Cancer Metastasis Rev 2008; 27:11-8.
48. Salgado R, Junius S, Benoy I, Van Dam P, Vermeulen P, Van Marck E, et al. Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. Int J Cancer 2003; 103:642-6.
49. Schlaepfer DD, Hou S, Lim ST, Tomar A, Yu H, Lim Y, et al. Tumor necrosis factor-alpha stimulates focal adhesion kinase activity required for mitogen-activated kinase-associated interleukin 6 expression. J Biol Chem 2007; 282:17450-9.
50. Earley S, Plopper GE. Phosphorylation of focal adhesion kinase promotes extravasation of breast cancer cells. Biochem Biophys Res Commun 2008; 366:476-82.